Gilead numbers ‘uninspiring’

TheStreet's Adam Feuerstein rated Gilead Science's second quarter numbers "uninspiring," with strong top-line results and a disappointment in earnings. As one of the few profitable biotechs in the market, though, the analysts concluded that a record of strong results would likely entice investors willing to overlook any short-term weakness. Report